Gyroscope Therapeutics Holdings plc

Syndicate wins an exit 11 weeks after announcement of series A round to fund development of Phase II-ready asset from Hengrui

Start-up, which launched with a $245M series A, is taking on AstraZeneca-Amgen drug with a mAb in-licensed from China-based Hengrui

Plus: Moderna, Immatics in oncology discovery, development deal, and updates from Takeda, Novartis, Crinetics, Verona, Nestlé

Plus: Approval for Pfizer’s MM bispecific and updates from Harmony-Zynerba, One Bio-Hengrui, Taysha, Arcturus, BioXcel 

VCs back start-up in £96M series A, joining AGTC takeout with pair of preclinical programs

Plus: Manion to lead Aclaris and a new CTO at Optibrium

Plus Alpine pivots and updates from Resolve, Imjudo, Syncona and more

Shares slide after C3 inhibitor fails on CATALINA study’s primary endpoint

Plus new CFO, CSO at Voyager and updates from Sonoma, Garuda, Alloy, Homology and more

U.K.-based VC taps Bosley, BioMotiv’s Jindal as it builds U.S. team; hires Syncona’s Schmidt in U.K.